Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242527 · ClinicalTrials.gov registry record · Phase 2
Epanova® for Lowering Very High Triglycerides
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
NCT01242527 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 399 participants.
The verdict
NCT01242527, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
Interventions
- DRUG placebo
- DRUG omefas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242527
The ClinicalTrials.gov registry entry for NCT01242527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 399 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01242527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01242527 about?
NCT01242527 is a clinical study titled "Epanova® for Lowering Very High Triglycerides". The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
What is the current status of trial NCT01242527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2011-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01242527?
The interventions under investigation include: placebo (DRUG), omefas (DRUG).
Who is sponsoring clinical trial NCT01242527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.